Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?
about
Desmopressin for treating nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaAdd-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin.Promising molecular targets and biomarkers for male BPH and LUTSNocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011.Nocturia: current concepts and future perspectives.Current pharmacotherapy of nocturia.Management of nocturia: the role of antidiuretic pharmacotherapy.Terminology, epidemiology, etiology, and pathophysiology of nocturia.Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia.Nocturia treatment outcomes: Analysis of contributory frequency volume chart parameters.Desmopressin for treating nocturia in men.Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.Self-rated sleep characteristics and bother from nocturia.Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.Comparison of nocturia response to desmopressin treatment between patients with normal and high nocturnal bladder capacity index.
P2860
Q24186670-0BB71972-B97B-4A15-8AC6-EA74808EBCE4Q36012645-0DDF4D33-7883-4BF6-807E-3EA7F10A6EA2Q36632651-E5154A9A-9548-4D93-9ED7-0263EA59BFE2Q37364472-63AF5491-1A62-4D8D-9FEA-A03E334CA90FQ37993502-86D561E8-7183-4469-AA87-B8A4C6870D42Q38049167-F4B45F87-DEE6-4BEB-935A-DF37388A8E93Q38095986-CAC9410E-AB1C-4D16-B4BD-DD82F1F9A644Q38204321-5F715124-634E-433A-BF5F-83CDD1B7652DQ38204322-31196D70-D0A2-4C59-9B39-0F154E7E3BE5Q45329229-6FBA52C1-6717-4BB2-9442-B7B8DF10E7DAQ46691749-E3D65C53-BBE9-46CB-B8E2-EDB0AF6CB663Q47746212-BBAB41D8-3C50-4129-A816-71829266FB1FQ47750340-7DFDB2D0-D753-4AA8-89E4-8502734DE132Q48252319-CF42ABD6-730D-402B-9A3F-62A3DF50661CQ48257227-F329F995-A8C0-48CD-B0DE-29973852794EQ50611571-618F880C-116C-413B-9AE9-C255369108AAQ54613905-2B7EC5A8-5A2B-4976-8D53-71362006914D
P2860
Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes of pharmacological ma ...... equal clinically significant?
@en
Outcomes of pharmacological ma ...... equal clinically significant?
@nl
type
label
Outcomes of pharmacological ma ...... equal clinically significant?
@en
Outcomes of pharmacological ma ...... equal clinically significant?
@nl
prefLabel
Outcomes of pharmacological ma ...... equal clinically significant?
@en
Outcomes of pharmacological ma ...... equal clinically significant?
@nl
P2860
P1433
P1476
Outcomes of pharmacological ma ...... equal clinically significant?
@en
P2093
Ariana L Smith
P2860
P304
P356
10.1111/J.1464-410X.2010.09972.X
P50
P577
2011-05-01T00:00:00Z